Table 2.
Pathological features by different immunohistochemical scores in HER-2 negative breast cancer.
| HER2-0 (n = 246) |
HER2-Low (n = 369) |
p Value * | |
|---|---|---|---|
| Grade | 0.0001 * | ||
| I | 32 (13.0%) | 64 (17.3%) | |
| II | 119 (48.4%) | 234 (63.4%) | |
| III NA |
86 (35.0%) 9 (3.6%) |
67 (18.2%) 4 (1.1%) |
|
| ER | 0.0001 * | ||
| Negative (<1%) | 73 (29.7%) | 46 (12.5%) | |
| Positive (≥1%) | 173 (70.3%) | 323 (87.5%) | |
| PR | 0.0001 * | ||
| Negative (<1%) | 90 (36.6%) | 83 (22.5%) | |
| Positive (≥1%) | 156 (63.4%) | 286 (77.5%) | |
| Ki-67 | 0.0001 * | ||
| <30% | 120 (48.8%) | 249 (67.5%) | |
| ≥30% | 120 (48.8%) | 117 (31.7%) | |
| NA | 6 (2.4%) | 3 (0.8%) |
ER, estrogen receptor; PR, progesterone receptor; NA, not available; HER2-0, HER2 immunohistochemistry score = 0; HER2-low was defined as HER2 immunohistochemistry score (+/++ with FISH (-); * p value via Chi-Square or Fisher exact test.